Pharma major Lupin has received final approval from USFDA for Bupropion Hydrochloride tablets used for the treatment of major depressive disorder.
The company has "received final approval for its Bupropion Hydrochloride extended release tablets USP (XL), 150 mg and 300 mg, from the United States Food and Drug Administration (USFDA)," Lupin said in a BSE filing today.
The company's product is the AB rated generic equivalent to Valeant Pharmaceuticals North America LLC's Wellbutrin tablets.
The drug is used for the treatment of major depressive disorder and prevention of seasonal affective order in adults, the filing said.
As per IMS MAT December 2016 data, Wellbutrin tablets have sales of USD 755 million in the US market.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)